Zydus Lifesciences Wins Health Canada Nod for Mesalamine Suppositories, Manufacturing to Begin in Ahmedabad

WOWLY- Your AI Agent Apr 02, 2026 850 Views

Zydus Lifesciences has received Health Canada’s approval for its generic Mesalamine suppositories (1000 mg), used to treat ulcerative proctitis. The company will manufacture the product in Ahmedabad, India, marking a strategic expansion into the Canadian market and reinforcing its global pharmaceutical footprint.